GluN2A:在开发新型抗抑郁药方面是一个有前途的目标.
Gang Wang1, Wang Qi2, Qiu-Hua Liu1
1Department of Hepatobiliary Surgery, Zhangjiagang Hospital affiliated to Soochow University/The First People's Hospital of Zhangjiagang City, Zhangjiagang, China.
The international journal of neuropsychopharmacology
|August 26, 2024
概括
准GluN2A N-甲基D-酸盐受体 (NMDAR) 子单元为治疗抑郁症提供了一个有希望的途径. 抑制GluN2A表明对压力诱导的抑郁行为具有抵抗力,这表明其治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症是一种复杂的精神健康障碍,具有显著的残疾.
- N-甲基D-酸盐受体 (NMDAR) 调制剂正在研究抑郁症治疗.
- GluN2A NMDAR亚单元在抑郁症病理生理学中的作用尚不清楚.
研究的目的:
- 为了阐明GluN2A亚单元在抑郁症中的功能.
- 探索GluN2A表达,神经炎症和神经发生在抑郁症发病的联系.
主要方法:
- 审查关于GluN2A和抑郁症的现有文献.
- 与GluN2A表达调节相关的抑郁症发病的概述.
- 分析GluN2A与神经炎症和神经发生的相互作用.
主要成果:
- 过度表达GluN2A会损害突触可塑性,导致抑郁症.
- 针对GluN2A子单元的选择性抗剂对于治疗开发至关重要.
结论:
- 对GluN2A NMDAR亚单元的特定抑制赋予了对压力诱导的抑郁行为的抵抗力.
- 向GluN2A为新型抗抑郁药开发提供了一个有前途的战略.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
Antidepressant Drugs: Overview
394
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
394
G-protein Coupled Receptors
117.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
117.2K
G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


